Comprehensive metabolic profiling of Alismatis Rhizoma triterpenes in rats based on characteristic ions and a triterpene database

Lu Wang,Sen Li,Jiaxin Li,Zhongzhe Cheng,Yulin Feng,Hui Ouyang,Zhifeng Du,Hongliang Jiang
DOI: https://doi.org/10.1016/j.jpha.2020.03.010
IF: 14.026
2021-02-01
Journal of Pharmaceutical Analysis
Abstract:The in <em>vivo</em> metabolites of triterpenes in ARE was characterized by characteristic ions and database.Mutual transformation of known triterpenes in <em>vivo</em> was confirmed for the first time.85 prototype compounds and 148 metabolites were identified in <em>vivo.</em>This work is the most comprehensive study for metabolism of AR to date.Alismatis Rhizoma (AR) is widely used in Chinese medicine, and its major bioactive components, triterpenes, reportedly possess various pharmacology activities. Therefore, it is very important to study the metabolism of triterpenes <em>in vivo</em>. However, the metabolism of <em>AR</em> triterpene extract has not been comprehensively elucidated due to its complex chemical components and metabolic pathways. In this study, an ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry method, which was based on the characteristic ions from an established database of known triterpenes, was used to analyze the major metabolites in rats following the oral administration of <em>Alismatis Rhizoma</em> extracts (ARE). As a result, a total of 233 constituents, with 85 prototype compounds and 148 metabolites, were identified for the first time. Hydrogenation, oxidation, sulfate and glucuronidation conjugation were the major metabolic pathways for triterpenes in AR. In addition, the mutual <em>in vivo</em> transformation of known ARE triterpenes was discovered and confirmed for the first time. Those results provide comprehensive insight into the metabolism of AR <em>in vivo</em>, which will be useful for future studies on its pharmacodynamics and pharmacokinetics. Moreover, this established strategy might be useful in metabolic studies of similar compounds.<span class="display"><span><ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2095177919309219-fx1_lrg.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download high-res image (152KB)</span></span></a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2095177919309219-fx1.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download full-size image</span></span></a></li></ol></span></span>
pharmacology & pharmacy
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to comprehensively analyze the metabolic profile of triterpenoids in Alismatis Rhizoma (AR) in rats. Specifically, due to the complexity of triterpenoid components in AR and the diversity of metabolic pathways, previous studies have failed to fully elucidate the in - vivo metabolism of these components. Therefore, this study aims to systematically analyze the main metabolites after rats are orally administered with Alismatis Rhizoma extract by establishing an ultra - high - performance liquid chromatography - quadrupole time - of - flight mass spectrometry (UHPLC - QTOF - MS/MS) method based on characteristic ions and a triterpenoid database, thereby filling this gap in this field. The key points of the study include: 1. **Comprehensive analysis of the metabolic profile**: Through UHPLC - QTOF - MS/MS technology, identify the metabolites produced by Alismatis Rhizoma extract in rats, especially the prototype compounds and their metabolites. 2. **Application of characteristic ions**: Utilize the characteristic ions of known triterpenoid compounds to establish a database for rapid and accurate identification of metabolites. 3. **Determination of metabolic pathways**: Determine the main metabolic pathways, such as hydrogenation, oxidation, sulfation, and glucuronidation, etc., and explore the influence of different metabolic pathways on triterpenoid compounds. 4. **Discovery of tautomeric phenomena**: For the first time, discover and confirm the in - vivo interconversion phenomenon of known triterpenoid compounds in Alismatis Rhizoma extract. Through these studies, the paper provides important basic data for future pharmacological and pharmacokinetic studies of Alismatis Rhizoma and an effective strategy for the metabolic studies of similar compounds.